Peter StÃ¤rkel

List of Publications by Year in descending order

89 papers	6,272 citations	101384 36 h-index	71532 76 g-index
91 all docs	91 docs citations	91 times ranked	6935 citing authors

#	Article	IF	Citations
1	Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4485-93.	3.3	652
2	Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature, 2019, 575, 505-511.	13.7	493
3	Intestinal fungi contribute to development of alcoholic liver disease. Journal of Clinical Investigation, 2017, 127, 2829-2841.	3.9	336
4	Intestinal REG3 Lectins Protect against Alcoholic Steatohepatitis by Reducing Mucosa-Associated Microbiota and Preventing Bacterial Translocation. Cell Host and Microbe, 2016, 19, 227-239.	5.1	284
5	Supplementation of Saturated Long-Chain Fatty Acids Maintains Intestinal Eubiosis and Reduces Ethanol-induced Liver Injury in Mice. Gastroenterology, 2015, 148, 203-214.e16.	0.6	266
6	Dysbiosisâ€induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice. Hepatology, 2015, 61, 883-894.	3.6	245
7	Role of intestinal permeability and inflammation in the biological and behavioral control of alcohol-dependent subjects. Brain, Behavior, and Immunity, 2012, 26, 911-918.	2.0	237
8	Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice. Gut, 2019, 68, 1504-1515.	6.1	202
9	The Ras/<scp>MAPK</scp> pathway and hepatocarcinoma: pathogenesis and therapeutic implications. European Journal of Clinical Investigation, 2015, 45, 609-623.	1.7	193
10	Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. Hepatology, 2018, 67, 2150-2166.	3.6	189
11	Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology, 2013, 58, 108-119.	3.6	187
12	Role of Inflammatory Pathways, Blood Mononuclear Cells, and Gut-Derived Bacterial Products in Alcohol Dependence. Biological Psychiatry, 2014, 76, 725-733.	0.7	163
13	Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis. Hepatology, 2020, 71, 522-538.	3.6	151
14	Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. Journal of Hepatology, 2018, 69, 396-405.	1.8	144
15	Intensive Enteral Nutrition Is Ineffective for Patients With Severe Alcoholic Hepatitis Treated With Corticosteroids. Gastroenterology, 2016, 150, 903-910.e8.	0.6	131
16	Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development. Journal of Clinical and Translational Hepatology, 2015, 3, 53-66.	0.7	130
17	Oxidative stress, KLF6 and transforming growth factor-Î² up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. Journal of Hepatology, 2003, 39, 538-546.	1.8	129
18	Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis. Nature Communications, 2019, 10, 3126.	5.8	124

#	Article	IF	Citations
19	The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease. Journal of Hepatology, 2020, 72, 391-400.	1.8	119
20	Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease. Gastroenterology, 2020, 159, 1839-1852.	0.6	103
21	Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood. Hepatology, 2017, 65, 475-490.	3.6	91
22	Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis. The Lancet Gastroenterology and Hepatology, 2018, 3, 614-625.	3.7	91
23	Gut Microbiota-Induced Changes in Î²-Hydroxybutyrate Metabolism Are Linked to Altered Sociability and Depression in Alcohol Use Disorder. Cell Reports, 2020, 33, 108238.	2.9	87
24	Bidirectional Communication between Liver and Gut during Alcoholic Liver Disease. Seminars in Liver Disease, 2016, 36, 331-339.	1.8	84
25	Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans. Gut Microbes, 2020, 12, 1782157.	4.3	83
26	Intestinal dysbiosis and permeability: the yin and yang in alcohol dependence and alcoholic liver disease. Clinical Science, 2018, 132, 199-212.	1.8	78
27	Intestinal Virome in Patients With Alcoholic Hepatitis. Hepatology, 2020, 72, 2182-2196.	3.6	74
28	A role for the peripheral immune system in the development of alcohol use disorders?. Neuropharmacology, 2017, 122, 148-160.	2.0	66
29	Linalool induces cell cycle arrest and apoptosis in HepG2 cells through oxidative stress generation and modulation of Ras/MAPK and Akt/mTOR pathways. Life Sciences, 2018, 199, 48-59.	2.0	66
30	The fecal mycobiome in non-alcoholic fatty liver disease. Journal of Hepatology, 2022, 76, 788-799.	1.8	66
31	Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1Î± Transactivation in Steatohepatitis. Cell Metabolism, 2018, 27, 339-350.e3.	7.2	62
32	Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients. Liver Transplantation, 2005, 11, 1228-1234.	1.3	58
33	The Loss of Metabolic Control on Alcohol Drinking in Heavy Drinking Alcohol-Dependent Subjects. PLoS ONE, 2012, 7, e38682.	1.1	58
34	Ductular Reaction Cells Display an Inflammatory Profile and Recruit Neutrophils in Alcoholic Hepatitis. Hepatology, 2019, 69, 2180-2195.	3.6	52
35	A dysbiotic subpopulation of alcohol-dependent subjects. Gut Microbes, 2015, 6, 388-391.	4.3	49
36	1,8-Cineole promotes G0/G1 cell cycle arrest and oxidative stress-induced senescence in HepG2 cells and sensitizes cells to anti-senescence drugs. Life Sciences, 2020, 243, 117271.	2.0	47

#	Article	IF	Citations
37	Dynamic Changes of the Fungal Microbiome in Alcohol Use Disorder. Frontiers in Physiology, 2021, 12, 699253.	1.3	45
38	The gut microbiota: A new target in the management of alcohol dependence?. Alcohol, 2019, 74, 105-111.	0.8	36
39	Serum and Fecal Oxylipins in Patients with Alcohol-Related Liver Disease. Digestive Diseases and Sciences, 2019, 64, 1878-1892.	1.1	35
40	Alterations of kynurenine pathway in alcohol use disorder and abstinence: a link with gut microbiota, peripheral inflammation and psychological symptoms. Translational Psychiatry, 2021, 11, 503.	2.4	32
41	NFÎºB, cytokines, TLR 3 and 7 expression in human endâ€stage HCV and alcoholic liver disease. European Journal of Clinical Investigation, 2010, 40, 575-584.	1.7	28
42	Deficient Stat3 DNA-binding is associated with high Pias3 expression and a positive anti-apoptotic balance in human end-stage alcoholic and hepatitis C cirrhosis. Journal of Hepatology, 2005, 43, 687-695.	1.8	26
43	Treatment of severe alcoholic hepatitis: past, present and future. European Journal of Clinical Investigation, 2017, 47, 531-539.	1.7	25
44	Deficient ILâ€6/Stat3 Signaling, High TLR7, and Type I Interferons in Early Human Alcoholic Liver Disease: A Triad for Liver Damage and Fibrosis. Hepatology Communications, 2019, 3, 867-882.	2.0	24
45	Intestinal iNKT cells migrate to liver and contribute to hepatocyte apoptosis during alcoholic liver disease. American Journal of Physiology - Renal Physiology, 2019, 316, G585-G597.	1.6	23
46	Functional Microbiomics Reveals Alterations of the Gut Microbiome and Host Coâ€Metabolism in Patients With Alcoholic Hepatitis. Hepatology Communications, 2020, 4, 1168-1182.	2.0	22
47	The gut mycobiome: a novel player in chronic liver diseases. Journal of Gastroenterology, 2021, 56, 1-11.	2.3	22
48	Chronic liver injury promotes hepatocarcinoma cell seeding and growth, associated with infiltration by macrophages. Cancer Science, 2018, 109, 2141-2152.	1.7	21
49	Expression and DNA-Binding Activity of Signal Transducer and Activator of Transcription 3 in Alcoholic Cirrhosis Compared to Normal Liver and Primary Biliary Cirrhosis in Humans. American Journal of Pathology, 2003, 162, 587-596.	1.9	20
50	Critical Role of LSEC in Post-Hepatectomy Liver Regeneration and Failure. International Journal of Molecular Sciences, 2021, 22, 8053.	1.8	20
51	Role of signal transducer and activator of transcription 3 in liver fibrosis progression in chronic hepatitis C-infected patients. Laboratory Investigation, 2007, 87, 173-181.	1.7	18
52	Intestinal virome in patients with alcohol use disorder and after abstinence. Hepatology Communications, 2022, 6, 2058-2069.	2.0	18
53	Tumor reoxygenation following administration of Mitogen-Activated Protein Kinase inhibitors: A rationale for combination with radiation therapy. Radiotherapy and Oncology, 2012, 105, 64-71.	0.3	17
54	Clinical, histological and molecular profiling of different stages of alcohol-related liver disease. Gut, 2022, 71, 1856-1866.	6.1	17

#	Article	IF	Citations
55	Participation of liver progenitor cells in liver regeneration: lack of evidence in the AAF/PH rat model. Laboratory Investigation, 2012, 92, 72-81.	1.7	15
56	Fibroscan Reliably Rules Out Advanced Liver Fibrosis and Significant Portal Hypertension in Alcoholic Patients. Journal of Clinical Gastroenterology, 2019, 53, 772-778.	1.1	15
57	Restoring an adequate dietary fiber intake by inulin supplementation: a pilot study showing an impact on gut microbiota and sociability in alcohol use disorder patients. Gut Microbes, 2022, 14, 2007042.	4.3	15
58	Antiviral therapy and fibrosis progression in patients with mildâ€“moderate hepatitis C recurrence after liver transplantation. A randomized controlled study. Digestive and Liver Disease, 2012, 44, 603-609.	0.4	12
59	Impact of PPAR-Î± induction on glucose homoeostasis in alcohol-fed mice. Clinical Science, 2013, 125, 501-511.	1.8	12
60	Ras in digestive oncology. Current Opinion in Oncology, 2014, 26, 454-461.	1.1	11
61	Functional Microbial Responses to Alcohol Abstinence in Patients With Alcohol Use Disorder. Frontiers in Physiology, 2020, 11, 370.	1.3	11
62	Deficiency of Intestinal Î±1â€2â€Fucosylation Exacerbates Ethanolâ€Induced Liver Disease in Mice. Alcoholism: Clinical and Experimental Research, 2020, 44, 1842-1851.	1.4	11
63	Dietary fiber deficiency as a component of malnutrition associated with psychological alterations in alcohol use disorder. Clinical Nutrition, 2021, 40, 2673-2682.	2.3	11
64	Host Factors in Dysregulation of the Gut Barrier Function during Alcohol-Associated Liver Disease. International Journal of Molecular Sciences, 2021, 22, 12687.	1.8	10
65	Blunted DNA synthesis and delayed S-phase entry following inhibition of Cdk2 activity in the regenerating rat liver. Laboratory Investigation, 2005, 85, 562-571.	1.7	8
66	Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium. PLoS ONE, 2017, 12, e0170933.	1.1	8
67	Ras inhibition in hepatocarcinoma by Sâ€transâ€transâ€farnesylthiosalicyclic acid: Association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis. Molecular Carcinogenesis, 2012, 51, 816-825.	1.3	7
68	Liver alterations are not improved by inulin supplementation in alcohol use disorder patients during alcohol withdrawal: A pilot randomized, double-blind, placebo-controlled study. EBioMedicine, 2022, 80, 104033.	2.7	7
69	To chew or not to chew: that's the question. Acta Clinica Belgica, 2016, 71, 187-189.	0.5	6
70	Tumoral response and tumoral phenotypic changes in a rat model of diethylnitrosamine-induced hepatocellular carcinoma after salirasib and sorafenib administration. OncoTargets and Therapy, 2018, Volume 11, 7143-7153.	1.0	6
71	Comparison of Sanger sequencing for hepatitis C virus genotyping with a commercial line probe assay in a tertiary hospital. BMC Infectious Diseases, 2019, 19, 738.	1.3	6
72	Frailty, sarcopenia and mortality in cirrhosis: what is the best assessment, how to interpret the data correctly and what interventions are possible?. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101661.	0.7	6

#	Article	IF	Citations
73	Lipidomics for the Prediction of Progressive Liver Disease in Patients with Alcohol Use Disorder. Metabolites, 2022, 12, 433.	1.3	6
74	Genetic factors predicting response to interferon treatment for viral hepatitis C. Gut, 2007, 57, 440-442.	6.1	5
75	New imaging assisted methods for liver fibrosis quantification: Is it really favorable to classical transient elastography?. Journal of Hepatology, 2015, 63, 765-766.	1.8	5
76	Tetrahydro Iso-Alpha Acids and Hexahydro Iso-Alpha Acids from Hops Inhibit Proliferation of Human Hepatocarcinoma Cell Lines and Reduce Diethylnitrosamine Induced Liver Tumor Formation in Rats. Nutrition and Cancer, 2015, 67, 748-760.	0.9	5
77	Muscle mass depletion in chronic liver diseases: An accelerated model of aging or a distinct entity?. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101721.	0.7	5
78	Limited lamivudine and long-term hepatitis B immunoglobulin immunoprophylaxis for prevention of hepatitis B recurrence after liver transplantation. Transplantation, 2002, 74, 408-410.	0.5	4
79	Liver Decompensation after Bariatric Surgery in the Absence of Cirrhosis. Obesity Surgery, 2022, 32, 1227-1235.	1.1	4
80	Integrative Analysis of Metabolome and Microbiome in Patients with Progressive Alcohol-Associated Liver Disease. Metabolites, 2021, 11, 766.	1.3	3
81	246 â€“ Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients with Alcoholic Hepatitis. Gastroenterology, 2019, 156, S-1186.	0.6	2
82	Research update for articles published in EJCI in 2008. European Journal of Clinical Investigation, 2010, 40, 770-789.	1.7	1
83	Research update for articles published in EJCI in 2010. European Journal of Clinical Investigation, 2012, 42, 1149-1164.	1.7	1
84	SAT-071-Insulin resistance in cirrhotic patients: results from a large prospective study. Journal of Hepatology, 2019, 70, e658-e659.	1.8	0
85	Virulence-related genes in fecal metagenomes associated with mortality in patients with alcoholic hepatitis. Journal of Hepatology, 2020, 73, S1-S2.	1.8	0
86	Defective gut adaptive immunity during early alcoholic liver disease. Journal of Hepatology, 2020, 73, S185-S186.	1.8	0
87	Que serait un dispositif hospitalier adÃ©quat au soutien de la transition chez les patients alcooliquesÂ?. Cahiers De Psychologie Clinique, 2021, nÂ° 57, 169-192.	0.1	0
88	Causal role of the gut microbiota in the development of behavioral alterations associated with alcohol dependence. Frontiers in Neuroscience, 0, 12, .	1.4	0
89	The Gut Microbiota Drives Metabolic Disorders Which Compromise Sociability in Alcoholic Patients. SSRN Electronic Journal, 0, , .	0.4	0